OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Verstovsek on the Potential Utility of Luspatercept in Myelofibrosis

April 15th 2021

Srdan Verstovsek, MD, PhD, discusses the potential clinical utility of luspatercept-aamt in myelofibrosis.

Dr. O’Malley on the Results of the KEYNOTE-775 Trial in Endometrial Cancer

April 15th 2021

David M. O'Malley, MD, discusses the results of the phase 3 KEYNOTE-775 trial in advanced endometrial cancer.

Dr. Saba on Unique Characteristics of Nasopharyngeal Carcinoma

April 15th 2021

Nabil F. Saba, MD, FACP, discusses some of the unique characteristics of nasopharyngeal carcinoma.

Dr. Rogers on the Safety Profile of Ianalumab/Ibrutinib in CLL

April 14th 2021

Kerry A. Rogers, MD, discusses the safety profile of the combination of ianalumab plus ibrutinib, in patients with chronic lymphocytic leukemia.

Dr. Tagawa on the FDA Approval of Sacituzumab Govitecan in Advanced Urothelial Carcinoma

April 14th 2021

Scott T. Tagawa, MD, MS, FACP, discusses the FDA approval of sacituzumab govitecan-hziy in advanced urothelial carcinoma.

Dr. Strickler on the Need for Chemotherapy-Free Options in Third-Line Metastatic CRC

April 14th 2021

John H. Strickler, MD, discusses the need for additional chemotherapy-free options in the third-line setting for patients with metastatic colorectal cancer.

Dr. Atkins on the Role of Adjuvant Chemoradiation in Gastric Cancer

April 14th 2021

Katelyn M. Atkins, MD, PhD, discusses the role of adjuvant chemoradiation therapy in gastric cancer.

Dr. Costa on the Evolving Treatment Paradigm in Newly Diagnosed Multiple Myeloma

April 14th 2021

Luciano J. Costa, MD, PhD, discusses the evolving treatment paradigm in newly diagnosed multiple myeloma.

Dr. Till on Data With Liso-Cel Vs Other Products Under Examination in MCL

April 14th 2021

Brian Till, MD, discusses the safety and efficacy of lisocabtagene maraleucel compared with other products under exploration in patients with mantle cell lymphoma.

Dr. del Rio on Remaining Questions With the COVID-19 Vaccines

April 13th 2021

Carlos del Rio, MD, discusses remaining questions with the COVID-19 vaccines.

Dr. Vij on the Potential of CELMoDs in Relapsed/Refractory Multiple Myeloma

April 13th 2021

Ravi Vij, MD, MBA, discusses the potential of cereblon E3 ligase modulators in relapsed/refractory multiple myeloma.

Dr. Coveler on the Toxicity Profile of NUC-3373 in Metastatic CRC

April 13th 2021

Andrew Coveler, MD, discusses the toxicity profile of NUC-3373 in metastatic colorectal cancer.

Dr. Rogers on the Next Steps With Obinutuzumab/Ibrutinib/Venetoclax in CLL

April 12th 2021

Kerry A. Rogers, MD, discusses the next steps with the triplet combination of obinutuzumab, ibrutinib, and venetoclax in chronic lymphocytic leukemia.

Dr. Trent on the Role of Avapritinib in PDGFRA Exon 18+ GIST

April 9th 2021

Jonathan C. Trent, MD, PhD, discusses the role of avapritinib in PDGFRA exon 18–positive gastrointestinal stromal tumor.

Dr. Wei on the Risk of ILD With Trastuzumab Deruxtecan in HER2+ Breast Cancer

April 9th 2021

Mei Wei, MD, discusses the risk of interstitial lung disease with fam-trastuzumab deruxtecan-nxki in HER2-positive breast cancer.

Dr. Barr on the Next Steps With Umbralisib/Ublituximab/Venetoclax in CLL

April 9th 2021

Paul M. Barr, MD, discusses the next steps with the combination of umbralisib, ublituximab, and venetoclax in chronic lymphocytic leukemia.

Dr. Levy on the Safety Profile, Dosing of Cabozantinib in HCC

April 9th 2021

Anna T. Levy, DO, discuses the safety profile and appropriate dosing of cabozantinib in patients with hepatocellular carcinoma.

Dr. Barr on the Safety Profile of Umbralisib/Ublituximab/Venetoclax in CLL

April 8th 2021

Paul M. Barr, MD, discusses the safety profile of umbralisib plus ublituximab and venetoclax in chronic lymphocytic leukemia.

Dr. Murphy on Remaining Questions With SBRT in Pediatric Sarcoma

April 8th 2021

Erin Murphy, MD, discusses remaining questions with stereotactic body radiotherapy in pediatric sarcoma.

Dr. Goy on the Clinical Implications of CAR T-Cell Therapy in MCL

April 8th 2021

Andre Goy, MD, discusses the clinical implications of CAR T-cell therapy in mantle cell lymphoma.